Chabiotech Co.,Ltd. (KOSDAQ:085660)

Market Cap	868.18B
Revenue (ttm)	1.15T
Net Income (ttm)	-76.25B
Shares Out	75.96M
EPS (ttm)	-1,338.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	327,787
Average Volume	192,994
Open	11,490
Previous Close	11,430
Day's Range	11,090 - 11,520
52-Week Range	9,260 - 18,480
Beta	0.42
RSI	60.47
Earnings Date	Nov 13, 2025

About Chabiotech

Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and developm...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 278
• Stock Exchange: KOSDAQ
• Ticker Symbol: 085660

Financial Performance

In 2024, Chabiotech's revenue was 1.05 trillion, an increase of 9.55% compared to the previous year's 953.95 billion. Losses were -8.05 billion, -4.48% less than in 2023.